Stay up-to-date with all the local and international news from the HARTMANN GROUP.

As part of its transformation program, the HARTMANN GROUP will invest a total of approximately 40 million euros in the production site at Herbrechtingen between 2021 and 2023. 20 million will be used for a new production line and a further 20 million euros for the modernization of existing facilities and infrastructure.

The coronavirus pandemic continued to have a significant impact on HARTMANN's business development in the third quarter of 2021. Across all business segments, the Company generated revenue of EUR 1,704.9 million in the first nine months of the 2021 financial year. This equates to a moderate organic decline in revenue of -5.6% compared to the same period of the previous year. This means that the development of sales has been declining for three quarters in a row. In the third quarter of 2021 alone, profitability is at its lowest level in three years due to pandemic-related economic conditions in the market.

The impact of the coronavirus pandemic on the HARTMANN GROUP's business development did not significantly diminish in the first six months of financial year 2021. The positive effects resulting from the pandemic, which were clearly visible in 2020, declined considerably, in particular, the demand for disinfection products and personal protective equipment. At the same time, the pandemic’s negative effects have largely persisted. Also, rising raw material, freight and logistics costs had a negative impact on the development of the business segments.

The HARTMANN GROUP, a leading European provider of system solutions for medical applications and care, will become the official hygiene partner of the Allianz Arena for the new 2021/2022 season. Spectators at future sporting events in the Allianz Arena will be offered even greater safety thanks to a holistic hygiene concept.

The coronavirus pandemic remains the dominant issue in the current financial year for HARTMANN's European core sales markets. The growth in sales seen over the course of the extraordinary year 2020, however, did not continue. Sales increases in the Infection Management segment compensated for a declining development in all other segments.

The year 2020 was significantly affected by its transformation program and the Covid-19 pandemic. The improvement in key financial figures, with considerable organic sales growth and a strong increase in earnings, is mainly due to temporary effects of the pandemic. There is a high degree of forecast uncertainty for 2021 as the further development of the pandemic remains unclear. German/English version of press release in the link: Fiscal Year 2020

Michel Kuehn and Dr. Raymund Heinen set to retire and Stefan Grote appointed as Board Member for Incontinence Management.

In the first nine months of 2020, the HARTMANN GROUP generated sales revenues of EUR 1,820 million (previous year: EUR 1,615 million), organic sales growth of 15.4% and an adjusted EBITDA of EUR 207.1 million (adjusted EBITDA margin of 11.4%). During this period, the coronavirus pandemic continued to be the dominant factor in the development of the business.

In the first half of 2020, HARTMANN achieved strong organic sales growth of 16 percent and a significant improvement in earnings. The high demand for products to cope with the corona pandemic compensated for the Corona-related decline in other business areas. HARTMANN has therefore decided to raise its forecast for 2020. Detailed information can be found in the half-year report.

The coronavirus pandemic continued to dominate the second quarter of 2020. “During the coronavirus pandemic, the HARTMANN GROUP has lived up to its important responsibility as a company in the healthcare sector. In particular, we have largely been able to meet the increased demand for disinfectants and personal protective equipment, by making appropriate use of resources to increase production and expand sources of supply for individual product groups,” says Britta Fünfstück, CEO of the HARTMANN GROUP.

The coronavirus pandemic was the defining issue for the HARTMANN GROUP in the first quarter of 2020. The business was strengthened during the period as a result of increased customer demand for disinfectants and protective equipment, as well as intensive measures to increase production capacities and the procurement of supplies despite difficulties in supply markets. HARTMANN recorded strong organic sales growth of 11.9% and a significant improvement in results as compared to the same period in the previous year. Sales revenues were at a total of EUR 603.5 million, and adjusted EBITDA was at EUR 73.6 million.

Stefan Müller takes over the position of Chief Financial Officer (CFO) at PAUL HARTMANN AG as of July 1, 2020. The new CFO has many years of experience as CFO in various areas at ZEISS in Germany and the USA

Against the backdrop of the expected moderate sales growth, EBIT declined to EUR 104.4 million (previous year: EUR 123.2 million), in line with the forecast range. The challenges with respect to the earnings performance are strongly related to the difficult macroeconomic conditions within the markets as well as extensive regulatory requirements. In order to counteract this challenging earnings trend, HARTMANN initiated a comprehensive, five-year strategic transformation programme in 2019.